This article summarizes the current knowledge about the impact of EGFR versus KRAS mutations, among other mutations, on the tumor microenvironment and immunotherapy responses in lung cancer, highlighting the possible clinical implications for present and upcoming immunotherapy regiments, as well as emphasizing the gaps in the current knowledge that should be further investigated. Here, EGFR is linked to lung carcinoma.